Zacks Research upgraded shares of Afya (NASDAQ:AFYA – Free Report) from a strong sell rating to a hold rating in a report released on Monday morning,Zacks.com reports.
A number of other brokerages also recently issued reports on AFYA. JPMorgan Chase & Co. restated a “neutral” rating and set a $22.00 price target (down from $24.50) on shares of Afya in a report on Wednesday, January 7th. UBS Group reiterated a “neutral” rating and issued a $16.00 price objective (down from $18.00) on shares of Afya in a research report on Friday, January 16th. Weiss Ratings reissued a “hold (c)” rating on shares of Afya in a research note on Wednesday, January 21st. Sanford C. Bernstein upgraded Afya to a “market perform” rating in a report on Friday, January 16th. Finally, Wall Street Zen lowered Afya from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 31st. One research analyst has rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $17.30.
Get Our Latest Analysis on Afya
Afya Stock Down 1.1%
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. Daiwa Securities Group Inc. bought a new position in Afya in the 4th quarter valued at approximately $43,000. Militia Capital Partners LP bought a new stake in shares of Afya in the 2nd quarter worth $71,000. Quantbot Technologies LP bought a new stake in shares of Afya in the 2nd quarter worth $117,000. Van ECK Associates Corp raised its stake in shares of Afya by 15.7% in the third quarter. Van ECK Associates Corp now owns 10,170 shares of the company’s stock worth $159,000 after purchasing an additional 1,377 shares during the last quarter. Finally, State of Wyoming bought a new position in shares of Afya during the second quarter valued at $164,000. 88.02% of the stock is owned by hedge funds and other institutional investors.
Afya Company Profile
Afya Ltd. operates as a leading provider of medical education and training services in Brazil. The company offers a comprehensive suite of educational programs that span undergraduate medical degrees, residency exam preparation, continuing medical education (CME) and digital learning platforms. Through a network of partner institutions and its own campus operations, Afya supports students at every stage of the medical training continuum, from enrollment in medical schools to ongoing professional development for practicing physicians.
At the core of Afya’s offerings is its undergraduate medical program, delivered through a combination of in-person courses at affiliated campuses and fully digital curricula.
Read More
- Five stocks we like better than Afya
- The Next Commodity Crunch (bigger than oil?)
- What a Former CIA Agent Knows About the Coming Collapse
- The gold chart Wall Street is terrified of…
- I tried out Elon Musk’s new AI tech — it floored me
- “I just bought 10,000 shares of a $5 stock…”
Receive News & Ratings for Afya Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Afya and related companies with MarketBeat.com's FREE daily email newsletter.
